Genentech/Idec Rituxan Letter Warns Of Fatal Mucocutaneous Reactions
Executive Summary
Fatal mucocutaneous reactions to Genentech/Idec's Rituxan non-Hodgkin's lymphoma treatment are the subject of a "Dear Healthcare Provider" letter sent to oncologists May 8.